Multifactorial Analysis of Prognostic and Predictive Biomarkers in Triple Negative Breast Cancer Patients
Triple-negative breast cancer (TNBC) represents one of the most aggressive subtypes of breast cancer, characterized by the absence of key molecular targets including estrogen receptors (ER), progesterone receptors (PR), and HER2. This molecular profile significantly limits treatment modalities, esta...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bashkir State Medical University
2025-07-01
|
| Series: | Креативная хирургия и онкология |
| Subjects: | |
| Online Access: | https://www.surgonco.ru/jour/article/view/1086 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850050347833229312 |
|---|---|
| author | V. N. Pavlov M. F. Urmantsev R. F. Gilmanova J. A. Ismagilova M. R. Bakeev |
| author_facet | V. N. Pavlov M. F. Urmantsev R. F. Gilmanova J. A. Ismagilova M. R. Bakeev |
| author_sort | V. N. Pavlov |
| collection | DOAJ |
| description | Triple-negative breast cancer (TNBC) represents one of the most aggressive subtypes of breast cancer, characterized by the absence of key molecular targets including estrogen receptors (ER), progesterone receptors (PR), and HER2. This molecular profile significantly limits treatment modalities, establishing chemotherapy as the definitive treatment. The high rates of recurrences and metastasis, along with the lack of specific targeted therapies, make TNBC a major clinical challenge. This article evaluates critical prognostic and predictive biomarkers of TNBC, including BRCA1/BRCA2 gene mutations, PD-L1 expression, tumor-infiltrating lymphocytes (TILs), circulating tumor cells (CTCs), and circulating tumor DNA (ctDNA). These markers are pivotal for outcome prediction and treatment optimization. Moreover, a transformative approach to TNBC treatment is represented by personalized medicine based on molecular profiling supported by artificial intelligence (AI). The integration of artificial intelligence (AI) facilitates the analysis of substantial data sets, the accurate prediction of clinical outcomes, and the formulation of customized treatment strategies for individual patients. Thus, this article analyzes current data concerning prognostic and predictive markers of TNBC, with a particular emphasis on their clinical utility and the potential for personalized therapy. |
| format | Article |
| id | doaj-art-68890d330e8340be8709359780d4e272 |
| institution | DOAJ |
| issn | 2076-3093 2307-0501 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Bashkir State Medical University |
| record_format | Article |
| series | Креативная хирургия и онкология |
| spelling | doaj-art-68890d330e8340be8709359780d4e2722025-08-20T02:53:30ZengBashkir State Medical UniversityКреативная хирургия и онкология2076-30932307-05012025-07-0115213914810.24060/2076-3093-2025-15-2-43-52623Multifactorial Analysis of Prognostic and Predictive Biomarkers in Triple Negative Breast Cancer PatientsV. N. Pavlov0M. F. Urmantsev1R. F. Gilmanova2J. A. Ismagilova3M. R. Bakeev4Bashkir State Medical UniversityBashkir State Medical UniversityBashkir State Medical University ; Clinic of Bashkir State Medical UniversityBashkir State Medical UniversityBashkir State Medical UniversityTriple-negative breast cancer (TNBC) represents one of the most aggressive subtypes of breast cancer, characterized by the absence of key molecular targets including estrogen receptors (ER), progesterone receptors (PR), and HER2. This molecular profile significantly limits treatment modalities, establishing chemotherapy as the definitive treatment. The high rates of recurrences and metastasis, along with the lack of specific targeted therapies, make TNBC a major clinical challenge. This article evaluates critical prognostic and predictive biomarkers of TNBC, including BRCA1/BRCA2 gene mutations, PD-L1 expression, tumor-infiltrating lymphocytes (TILs), circulating tumor cells (CTCs), and circulating tumor DNA (ctDNA). These markers are pivotal for outcome prediction and treatment optimization. Moreover, a transformative approach to TNBC treatment is represented by personalized medicine based on molecular profiling supported by artificial intelligence (AI). The integration of artificial intelligence (AI) facilitates the analysis of substantial data sets, the accurate prediction of clinical outcomes, and the formulation of customized treatment strategies for individual patients. Thus, this article analyzes current data concerning prognostic and predictive markers of TNBC, with a particular emphasis on their clinical utility and the potential for personalized therapy.https://www.surgonco.ru/jour/article/view/1086triple-negative breast cancerprognostic and predictive biomarkerspersonalized medicinemolecular profilingartificial intelligenceimmunotherapy |
| spellingShingle | V. N. Pavlov M. F. Urmantsev R. F. Gilmanova J. A. Ismagilova M. R. Bakeev Multifactorial Analysis of Prognostic and Predictive Biomarkers in Triple Negative Breast Cancer Patients Креативная хирургия и онкология triple-negative breast cancer prognostic and predictive biomarkers personalized medicine molecular profiling artificial intelligence immunotherapy |
| title | Multifactorial Analysis of Prognostic and Predictive Biomarkers in Triple Negative Breast Cancer Patients |
| title_full | Multifactorial Analysis of Prognostic and Predictive Biomarkers in Triple Negative Breast Cancer Patients |
| title_fullStr | Multifactorial Analysis of Prognostic and Predictive Biomarkers in Triple Negative Breast Cancer Patients |
| title_full_unstemmed | Multifactorial Analysis of Prognostic and Predictive Biomarkers in Triple Negative Breast Cancer Patients |
| title_short | Multifactorial Analysis of Prognostic and Predictive Biomarkers in Triple Negative Breast Cancer Patients |
| title_sort | multifactorial analysis of prognostic and predictive biomarkers in triple negative breast cancer patients |
| topic | triple-negative breast cancer prognostic and predictive biomarkers personalized medicine molecular profiling artificial intelligence immunotherapy |
| url | https://www.surgonco.ru/jour/article/view/1086 |
| work_keys_str_mv | AT vnpavlov multifactorialanalysisofprognosticandpredictivebiomarkersintriplenegativebreastcancerpatients AT mfurmantsev multifactorialanalysisofprognosticandpredictivebiomarkersintriplenegativebreastcancerpatients AT rfgilmanova multifactorialanalysisofprognosticandpredictivebiomarkersintriplenegativebreastcancerpatients AT jaismagilova multifactorialanalysisofprognosticandpredictivebiomarkersintriplenegativebreastcancerpatients AT mrbakeev multifactorialanalysisofprognosticandpredictivebiomarkersintriplenegativebreastcancerpatients |